MP0112: Phase I/IIa data

Top-line data from a dose-escalation U.S. Phase I/IIa trial in 18 patients showed that a single intravitreal injection of MP0112 was well tolerated. Additionally, the therapeutic effect of MP0112 increased in a dose-dependent manner, with the high dose showing an effect beyond 16 weeks in most patients. Data were presented at the Association for Research in Vision and Ophthalmology meeting in May in Fort Lauderdale. ...